2/25/2020  5:29:58 PM Chg. -1.31 Volume Bid5:30:02 PM Ask5:30:03 PM Market Capitalization Dividend Y. P/E Ratio
90.46EUR -1.43% 292,708
Turnover: 26.65 mill.
90.32Bid Size: 49 90.56Ask Size: 49 112.79 bill.EUR 3.39% 26.21

Business description

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
 

Management board & Supervisory board

CEO
Paul Hudson
Management board
Jean-Baptiste Chasseloup de Chatillon, Alan Main, Ameet Nathwani, Bill Sibold, Caroline Luscombe, David Loew, Dieter Weinand, Dominique Carouge, Dr. John Reed, Karen Linehan, Kathleen Tregoning, Olivier Charmeil, Philippe Luscan
Supervisory board
Serge Weinberg, Bernard Charles, Carole Piwnica, Christian Mulliez, Christian Senectaire, Claudie Haigneré, Diane Souza, Emmanuel Babeau, Fabienne Lecorvaisier, Laurent Attal, Marion Palme, Melanie Lee, Patrick Kron, Paul Hudson, Suet-Fern Lee, Thomas Südhof
 

Company data

Name: Sanofi S.A.
Address: 54, Rue La Boétie,F-75008 Paris
Phone: +33-1-53-77-40-00
Fax: +33-1-53-77-43-03
E-mail: -
Internet: www.sanofi-aventis.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 88.80%
IPO date: -

Investor relations

Name: George Grofik
IR phone: +33-1-53-77-45-45
IR Fax: -
IR e-mail: ir@sanofi.com

Company calendar

CW 17 | 4/24/2020 Interim Report 1st Quarter/3 Months
CW 18 | 4/28/2020 General Shareholder Meeting
CW 31 | 7/29/2020 Interim Report 2nd Quarter/6 Months
CW 44 | 10/29/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
88.80%
L'Oréal
 
9.40%
Mitarbeiter
 
1.80%